Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.510
+0.040 (2.72%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Annovis Bio Employees
As of December 31, 2024, Annovis Bio had 15 total employees, including 8 full-time and 7 part-time employees. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,639,358
Market Cap
29.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ANVS News
- 27 days ago - Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewsWire
- 4 weeks ago - Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewsWire
- 4 weeks ago - Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewsWire
- 2 months ago - Annovis to Host Patients' Live Forum on February 27, 2025 - GlobeNewsWire
- 2 months ago - Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewsWire